AU2004199A - Method for reducing susceptibility to hiv infection - Google Patents

Method for reducing susceptibility to hiv infection Download PDF

Info

Publication number
AU2004199A
AU2004199A AU20041/99A AU2004199A AU2004199A AU 2004199 A AU2004199 A AU 2004199A AU 20041/99 A AU20041/99 A AU 20041/99A AU 2004199 A AU2004199 A AU 2004199A AU 2004199 A AU2004199 A AU 2004199A
Authority
AU
Australia
Prior art keywords
cd40l
cells
cell
hiv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20041/99A
Other languages
English (en)
Inventor
Elaine K. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU2004199A publication Critical patent/AU2004199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU20041/99A 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection Abandoned AU2004199A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6835597P 1997-12-19 1997-12-19
US60068355 1997-12-19
US9847498P 1998-08-31 1998-08-31
US60098474 1998-08-31
PCT/US1998/027005 WO1999032138A1 (en) 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection

Publications (1)

Publication Number Publication Date
AU2004199A true AU2004199A (en) 1999-07-12

Family

ID=26748884

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20041/99A Abandoned AU2004199A (en) 1997-12-19 1998-12-18 Method for reducing susceptibility to hiv infection

Country Status (6)

Country Link
EP (1) EP1059932A1 (de)
JP (1) JP2001526241A (de)
AU (1) AU2004199A (de)
CA (1) CA2313805A1 (de)
IL (1) IL136731A0 (de)
WO (1) WO1999032138A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
WO2002036141A2 (en) * 2000-11-02 2002-05-10 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US7175838B2 (en) * 2001-08-23 2007-02-13 The United States Of America Represented By The Department Of Health And Human Services Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
AU2006202318A1 (en) 2005-06-02 2006-12-21 Wing-Yee Chan The preparation of multipotent stem cells and the use thereof
DK2066339T3 (da) 2006-09-18 2014-11-03 Univ Arkansas Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
CN102037135A (zh) 2007-10-30 2011-04-27 阿肯色大学评议会 增强对有鞭毛的细菌的免疫反应的组合物和方法
CA3156538C (en) 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
EP2579901B1 (de) 2010-06-09 2019-08-07 The Board of Trustees of The University of Arkansas Impfstoff und verfahren zur linderung einer campylobacter-infektion
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
WO2017192671A1 (en) 2016-05-03 2017-11-09 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
NZ278740A (en) * 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
PT812206E (pt) * 1995-03-01 2002-11-29 Immunex Corp Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria

Also Published As

Publication number Publication date
CA2313805A1 (en) 1999-07-01
IL136731A0 (en) 2001-06-14
EP1059932A1 (de) 2000-12-20
JP2001526241A (ja) 2001-12-18
WO1999032138A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
Sim et al. The IL-2 cytokine family in cancer immunotherapy
CA2087525C (en) Adoptive immunotherapy with interleukin-7
Trinchieri et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
Tsutsui et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
US6303121B1 (en) Method of using human receptor protein 4-1BB
AU680102B2 (en) Method of preventing or treating disease characterized by neoplastic cells expressing CD40
AU693526B2 (en) Immuno-stimulatory monoclonal antibodies
US8178308B2 (en) Use of IL-27 agonists to increase interferon-gamma production
AU2004199A (en) Method for reducing susceptibility to hiv infection
Kornbluth The emerging role of CD40 ligand in HIV infection
Nagumo et al. Synergistic augmentative effect of interleukin‐10 and CD27/CD70 interactions on B‐cell immunoglobulin synthesis
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
Levitt et al. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
US20040258661A1 (en) Generation of use of tc1 and tc2 cells
US6074635A (en) T cell activation
Nguyen et al. Interleukin (IL)-15 enhances antibody-dependent cellular cytotoxicity and natural killer activity in neonatal cells
Bettens et al. Lymphokine gene expression related to CD4 T cell subset (CD45R/CDw29) phenotype conversion
Yamane et al. Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells
JP2022023136A (ja) Ｔ細胞の拡張及び活性化の方法
US6319493B1 (en) Treatment of neoplastic disease with interleukin-10
WO2000009150A2 (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
Zambello et al. IL‐12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes
Tompkins et al. Role of cytokines in feline retrovirus diseases and treatment
TW202332771A (zh) 轉基因免疫細胞及其構建方法和應用
WO2024108058A2 (en) Methods of inducing pd-l1 expression

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted